Matteo Lambertini is a medical oncologist specialized at the National Cancer Institute in Genova (Italy), currently working at the Institut Jules Bordet, a multidisciplinary center totally dedicated to cancer in Brussels (Belgium) under the supervision of Prof. Martine Piccart. He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research. Above all, he has a particular expertise in the management of breast cancer in young women, with a specific attention to both the fertility and pregnancy issues that they have to face after diagnosis. During his medical oncology training, he had the opportunity to work and collaborate with several national and international leading experts in the field; these experiences have played a crucial role to deepen his skills in the management of breast cancer in young women. He is part of the scientific board of the Italian Association of Medical Oncology (AIOM) clinical recommendations on fertility preservation in cancer patients. He has authored several publications in peer-reviewed journals and book chapters in the field of fertility preservation in breast cancer patients. His most important research conducted so far under the supervision of Dr. Lucia Del Mastro, addressed the role of administering luteinizing hormone-releasing hormone (LHRH) analogs during chemotherapy as a strategy to preserve ovarian function and fertility in early breast cancer patients who are candidates for cytotoxic therapy. Thanks to the support of the European Society for Medical Oncology (ESMO), he is currently working on a challenging PhD project at the Free University of Brussels (ULB) aiming to improve the understanding of many controversial aspects related to fertility and pregnancy issues in breast cancer patients, with the ultimate goal to further improve the care and quality of life of young survivors.